false 0001874252 00-0000000 0001874252 2026-11-20 2026-11-20 0001874252 dei:FormerAddressMember 2026-11-20 2026-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 20, 2026

 

Quantum Cyber N.V.

(Exact Name of Registrant as Specified in its Charter)

 

The Netherlands   001-41010   N/A

(State or Other Jurisdiction

of Incorporation)

  (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

38 Union Avenue, Bridgeport, CT 06607

(Address of Principal Executive Offices) (Zip Code)

 

+1 (203) 851-1599

(Registrant’s telephone number, including area code)

 

200 Connecticut Avenue, Suite 400, Norwalk, CT 06854

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of Each Exchange On Which Registered
Ordinary Shares, nominal value €0.01 per share   QUCY   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Resignation of William Caragol, Chief Financial Officer

 

On November 20, 2026, William Caragol notified Quantum Cyber N.V., a company organized under the laws of the Netherlands (the “Company”), of his resignation as the Company’s Chief Financial Officer, effective November 20, 2026. To support the transition, on November 20, 2026, Mr. Caragol entered into a consulting agreement with the Company, pursuant to which Mr. Caragol will receive a fee of $15,000 per month. In addition, all equity awards previously granted to Mr. Caragol pursuant to the Company’s 2025 Omnibus Incentive Plan (the “Plan”) will continue to vest in accordance with their existing vesting schedules and will remain outstanding and exercisable through their original ten-year terms, regardless of when Mr. Caragol ceases to provide services to the Company.

 

Appointment of David Caplon, Chief Financial Officer

 

In connection with Mr. Caragol’s resignation, on November 20, 2026, the Board of Directors of the Company (the “Board”) appointed David Caplon, age 33, to serve as Chief Financial Officer of the Company, effective November 20, 2026. In such capacity, Mr. Caplon will serve as the Company’s principal financial officer and principal accounting officer.

 

Mr. Caplon has served as the Company’s Controller since June 2026. Upon the effectiveness of his appointment as Chief Financial Officer, Mr. Caplon will no longer serve as Controller. Mr. Caplon has served as Corporate Controller of CapForce Inc. (formerly known as OpGen, Inc.), a capital markets advisory and financial technology company and formerly a molecular diagnostics company, since September 2022, and previously served as its Assistant Controller from March 2021 to September 2022. Mr. Caplon has also provided, and continues to provide, certain accounting and financial reporting services to other companies, none of which has constituted his principal occupation or employment. Mr. Caplon began his career in the audit practice of CohnReznick LLP, a public accounting firm, and subsequently held various corporate accounting and finance positions of increasing responsibility before joining CapForce Inc. Mr. Caplon holds a Bachelor of Science in Accounting and Finance from the University of Maryland, College Park, and is a Certified Public Accountant licensed in the Commonwealth of Virginia.

 

On November 20, 2026, in connection with Mr. Caplon’s appointment as Chief Financial Officer of the Company, the Company and Mr. Caplon entered into an executive employment agreement (the “Employment Agreement”). The Employment Agreement, which becomes effective on November 20, 2026 (the “Effective Date”), provides for, among other things, a base salary of $22,500 per month ($270,000 on an annualized basis), subject to review for increase at least annually. Mr. Caplon will be eligible to receive a target annual cash bonus equal to 100% of his annual base salary, as determined by the Compensation Committee of the Board based on the achievement of performance objectives, and annual equity awards under the Plan with a grant-date value of up to the greater of (i) the value of 250,000 ordinary shares and (ii) 100% of his annual base salary.

 

The Employment Agreement has an initial term of twelve months from the Effective Date and will automatically renew for successive six-month periods unless either party provides written notice of non-renewal at least 21 days before the end of the then-current term. A notice of non-renewal by the Company will be treated as a termination without cause for purposes of Mr. Caplon’s severance. If Mr. Caplon’s employment is terminated by the Company without cause or by reason of his death or disability, or by Mr. Caplon for good reason (each as defined in the Employment Agreement), subject to his execution of a general release of claims, Mr. Caplon will be entitled to (i) continued payment of his base salary for twelve months, (ii) a prorated target annual bonus for the year of termination, (iii) reimbursement of COBRA premiums for up to twelve months and (iv) accelerated vesting of the portion of his outstanding unvested equity awards that would have vested during the twelve months following termination, with vested stock options remaining exercisable for not less than twelve months following termination. Severance payments will cease if Mr. Caplon materially violates his restrictive covenant obligations. If Mr. Caplon’s employment is terminated by the Company without cause or by Mr. Caplon for good reason within twelve months following a change in control (as defined in the Employment Agreement), Mr. Caplon will instead be entitled to the same salary continuation, prorated target bonus and COBRA benefits, plus full vesting of all of his outstanding unvested equity awards. The Employment Agreement also contains confidentiality and intellectual property assignment covenants and non-solicitation covenants with respect to the Company’s employees and customers during the term and for one year following his employment, and provides for indemnification and advancement of expenses to the fullest extent permitted by applicable law and directors’ and officers’ liability insurance coverage for not less than six years following termination of his employment.

 

In addition, on November 20, 2026, Mr. Caplon was granted an option to purchase 170,000 ordinary shares of the Company, nominal value €0.01 per share, under the Plan (the “Promotion Option”). The Promotion Option has an exercise price per share equal to the closing price of an ordinary share on the Nasdaq Capital Market on the date of grant, and a term of ten years. The Promotion Option will vest in eighteen substantially equal monthly installments on each monthly anniversary of the date of grant, subject to Mr. Caplon’s continued employment through each vesting date and to the accelerated vesting provisions of the Employment Agreement described above.

 

There are no arrangements or understandings between Mr. Caplon and any other person pursuant to which Mr. Caplon was appointed Chief Financial Officer of the Company. Mr. Caplon does not have any family relationship with any of the Company’s directors or executive officers or any persons nominated or chosen by the Company to be a director or executive officer. Mr. Caplon does not have any direct or indirect material interest in any transaction or proposed transaction required to be reported under Item 404(a) of Regulation S-K.

 

The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

1

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
10.1   Employment Agreement, dated November 20, 2026, by and between David Caplon and Quantum Cyber N.V.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

2

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  QUANTUM CYBER N.V.
     
Date: November 20, 2026 By: /s/ David Lazar
  Name: David Lazar
  Title: Chief Executive Officer

 

3